Log In
Print this Print this

CR 2017

Also known as: Dexloxiglumide

  Manage Alerts
Collapse Summary General Information
Company Rottapharm Biotech s.r.l.
DescriptionSelective and reversible cholecystokinin (CCK) receptor antagonist
Molecular Target Cholecystokinin A receptor (CCKAR) (CCK1R)
Mechanism of ActionCholecystokinin receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationIrritable bowel syndrome
Indication DetailsTreat irritable bowel syndrome (IBS)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today